CURE OM - Leading the Way in Ocular Melanoma Research
The MRF's CURE OM initiative is leading the ocular melanoma (OM) field forward. We are committed to accelerating the development of effective treatments and, ultimately, a cure for this disease. Our scientific initiative is led by our international, interdisciplinary Scientific Steering Committee and includes research grants, biannual international scientific meetings and partnerships with leading organizations, including industry. These efforts ensure continued collaboration, support and coordination to move OM research forward.
In 2012, CURE OM began funding ocular melanoma-specific research grants. Falling under the MRF's general Research Grant Program, the research emphasizes both basic and clinical research projects that explore innovative approaches to understanding OM and its treatment. Proposals are submitted from around the world and undergo a rigorous peer-reviewed process by experts and leaders in the OM field. This helps us identify the most promising and impactful research to fund. Since 2012, over $1.2 million has been secured specifically for OM research and 7 different research awards - 5 Established Investigator Awards and 2 Junior Investigator Awards - have been funded. Please read about The CURE OM grant recipients are listed below, or learn about all of the MRF's previous award winners.
Most recently, in 2016, CURE OM offered two award opportunities:
- CURE OM Junior Fellowship Award, funded by an educational grant from AstraZeneca
- CURE OM Unite! Established Investigator Award - made possible by a grassroots fundraising effort by the CURE OM cummunity, #CUREOM Unite! Funds raised were matched by generous donors, Mark and Alison Weinzierl.
The Review Process
The MRF's scientific peer-review process ensures every research proposal submitted is reviewed by no less than two melanoma experts. This rigorous process involves hundreds of researchers from academic institutions throughout the United States and around the world. Each application is reviewed in both a quantitative and a qualitative process followed by a thorough assessment by a panel of melanoma researchers. Top proposals are considered by the Scientific Advisory Committee and a discussed at length by the MRF's Board of Directors.
After a successful grassroots fundraising effort with the 2015 #CUREOM Unite! campaign, a new Established Investigator Award was established. This award prompted the launch of the first patient and caregiver research grant review process, allowing the OM community to take part in the scientific review, helping ultimately determine the awardee.
CURE OM Grant Recipients
Andrew Aplin, PhD - Thomas Jefferson University - Regulation of the response to targeted inhibitors in uveal melanoma - Career Development Award - #CURE OM Unite! Grant and matching funds by Mark and Alison Weinierl
Jae Hyuk Yoo, PhD - University of Utah - Mechanism of metastasis in a less common molecular subset of uveal melanoma - CURE OM Junior Fellowship Award made possible by a grant from AstraZeneca
John Sondek, PhD - University of North Carolina at Chapel Hill - Fast cycling Gaq Ga11 - Established Investigator Award
William Tansey, PhD - Vanderbilt University Medical Center - MYC as an invisible driver in metastatic uveal melanoma - Established Investigator Award
Richard Carvajal, MD - Memorial Sloan-Kettering Cancer Center - Overcoming resistance to MEK inhibition in advanced uveal melanoma - Career Development Award
Levi Garraway, MD, PhD - Dana-Farber Cancer Institute - Dissecting therapeutic avenues in UM through genomic and functional studies - Established Investigator Award
John Sondek, PhD - University of North Carolina at Chapel Hill - Interdiction of signaling by G-alpha-q to treat ocular melanoma - Established Investigator Award
CURE OM Patient Registry
CURE OM is sponsoring a national patient-reported registry to support research advancement in ocular melanoma. The OM patient-registry will capture comprehensive disease data including: genetics and disease characteristics, environment, types of treatments, physical outcomes, and the patient’s quality of life. It will also inform patient-centered research initiatives focused on policy, patient preferences and standards of care. And in addition to collecting invaluable disease data the registry will support the collaboration of patients, caregivers, clinicians, researchers, and the pharmaceutical industry to find a cure together.
The 2016 CURE OM Unite! campaign supported the development and implementation of the registry. To date, CURE OM has established a working group currently focusing on integrating the registry into other initiatives around the world and setting the foundation to launch the registry in the coming year.
CURE OM hosts biannual international scientific meetings aimed at increasing collaboration in the OM field in order to accelerate treatment and research. Each meeting includes a diverse group of speakers and participants from around the world.
CURE OM has established important partnerships with leading research organizations, including the National Cancer Institute, the Society for Melanoma Research and the International Rare Cancers Initiative, just to name a few! We also work regularly with leading melanoma research institutions all over the world. Together, we are leading the way in finding a cure for ocular melanoma.